Rising Cases of Pneumonia during the COVID-19 Anticipated to Boost the Global Pneumonia Therapeutics Market - Exclusive Report [230] by Research Dive
13 oct. 2020 05h47 HE
|
Research Dive
New York, USA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- The latest research report on the global pneumonia therapeutics market by Research Dive reflects the influence of COVID-19 pandemic on the present...
Pneumonia Therapeutics Market to value USD 2.8 Bn by 2026: Global Market Insights, Inc.
23 juin 2020 04h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, June 23, 2020 (GLOBE NEWSWIRE) -- Global Market Insights, Inc. has recently added a new report on pneumonia therapeutics market which estimates the global market valuation...
Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors
20 avr. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - ...
Antiviral Drugs Market Worth USD 44.2 billion by 2026, at 3.2% CAGR; Rising Prevalence of HIV to Fuel Growth: Fortune Business Insights™
20 févr. 2020 07h37 HE
|
Fortune Business Insights
Pune, Feb. 20, 2020 (GLOBE NEWSWIRE) -- The global Antiviral Drugs Market is set to gain impetus from the improvements in research collaborations of industry giants to develop state-of-the-art...
Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses
01 oct. 2019 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update
10 mai 2019 08h35 HE
|
Cocrystal Pharma, Inc.
– Company is well positioned to achieve multiple corporate, clinical and research value-driving milestones in 2019 – BOTHELL, WA, May 10,...
Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
01 avr. 2019 08h35 HE
|
Cocrystal Pharma, Inc.
– Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to enable rapid advancement...
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
03 janv. 2019 08h30 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...